[{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ OrbiMed Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verrica Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Topical Film-Forming Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Jefferies LLC","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Jefferies LLC","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Jefferies LLC"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Ruxotemitide","moa":"Cell death","graph1":"Oncology","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Topical Film-Forming Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Verrica Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cantharidin","moa":"Phosphatase 2A","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Verrica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Verrica Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Verrica Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Verrica Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
